TY - JOUR
T1 - Targeted sequencing of established and candidate colorectal cancer genes in the Colon Cancer Family Registry Cohort
AU - Colon Cancer Family Registry (CCFR)
AU - Raskin, Leon
AU - Guo, Yan
AU - Du, Liping
AU - Clendenning, Mark
AU - Rosty, Christophe
AU - Lindor, Noralane M.
AU - Gruber, Stephen B.
AU - Buchanan, Daniel D.
N1 - Funding Information:
The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute any SEER program or any of the collaborating centers in the Colon Cancer Family Registry (CCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government, SEER or the CCFRThis work was supported by the NIH NCI Pathway to Independence Award K99/R00CA158141. This work was also supported in part by grant UM1 CA167551 from the National Cancer Institute and through cooperative agreements with the following Colon CFR centers: Australasian Colorectal Cancer Family Registry (U01 CA074778 and U01/U24 CA097735), Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01/U24 CA074800), Ontario Familial Colorectal Cancer Registry (U01/U24 CA074783), Seattle Colorectal Cancer Family Registry (U01/U24 CA074794), University of Hawaii Colorectal Cancer Family Registry (U01/U24 CA074806), USC Consortium Colorectal Cancer Family Registry U01/U24 CA074799), with additional support through grant R01 CA104132 (to L LeMarchand). Additional support was provided from the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute to Fred Hutchinson Cancer Research Center (Control Nos. N01-CN-67009 and N01-PC-35142, and Contract No. HHSN2612013000121), the Hawai'i Department of Health (Control Nos. N01-PC-67001 and N01-PC-35137, and Contract No. HHSN26120100037C, and the California Department of Public Health (contracts HHSN261201000140Cawarded to the Cancer Prevention Institute of California and HHSN261201000035C awarded to the University of Southern California.
Publisher Copyright:
© Raskin et al.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes associated with Mendelian cancer syndromes using next-generation sequencing (NGS) can be prohibitively expensive for studies requiring large samples sizes. The aim of the study was to identify rare single nucleotide variants and small indels in 40 established or candidate CRC susceptibility genes in 1,046 familial CRC cases (including both MSS and MSI-H tumor subtypes) and 1,006 unrelated controls from the Colon Cancer Family Registry Cohort using a robust and cost-effective DNA pooling NGS strategy. We identified 264 variants in 38 genes that were observed only in cases, comprising either very rare (minor allele frequency < 0.001) or not previously reported (n=90, 34%) in reference databases, including six stop-gain, three frameshift, and 255 nonsynonymous variants predicted to be damaging. We found novel germline mutations in established CRC genes MLH1, APC, and POLE, and likely pathogenic variants in cancer susceptibility genes BAP1, CDH1, CHEK2, ENG, and MSH3. For the candidate CRC genes, we identified likely pathogenic variants in the helicase domain of POLQ and in the LRIG1, SH2B3, and NOS1 genes and present their clinicopathological characteristics. Using a DNA pooling NGS strategy, we identified novel germline mutations in established CRC susceptibility genes in familial CRC cases. Further studies are required to support the role of POLQ, LRIG1, SH2B3 and NOS1 as CRC susceptibility genes.
AB - The underlying genetic cause of colorectal cancer (CRC) can be identified for 5-10% of all cases, while at least 20% of CRC cases are thought to be due to inherited genetic factors. Screening for highly penetrant mutations in genes associated with Mendelian cancer syndromes using next-generation sequencing (NGS) can be prohibitively expensive for studies requiring large samples sizes. The aim of the study was to identify rare single nucleotide variants and small indels in 40 established or candidate CRC susceptibility genes in 1,046 familial CRC cases (including both MSS and MSI-H tumor subtypes) and 1,006 unrelated controls from the Colon Cancer Family Registry Cohort using a robust and cost-effective DNA pooling NGS strategy. We identified 264 variants in 38 genes that were observed only in cases, comprising either very rare (minor allele frequency < 0.001) or not previously reported (n=90, 34%) in reference databases, including six stop-gain, three frameshift, and 255 nonsynonymous variants predicted to be damaging. We found novel germline mutations in established CRC genes MLH1, APC, and POLE, and likely pathogenic variants in cancer susceptibility genes BAP1, CDH1, CHEK2, ENG, and MSH3. For the candidate CRC genes, we identified likely pathogenic variants in the helicase domain of POLQ and in the LRIG1, SH2B3, and NOS1 genes and present their clinicopathological characteristics. Using a DNA pooling NGS strategy, we identified novel germline mutations in established CRC susceptibility genes in familial CRC cases. Further studies are required to support the role of POLQ, LRIG1, SH2B3 and NOS1 as CRC susceptibility genes.
KW - Colon Cancer Family Registry
KW - DNA pooling
KW - Hereditary colorectal cancer
KW - Rare variants
KW - Targeted sequencing
UR - http://www.scopus.com/inward/record.url?scp=85032891835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032891835&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.18596
DO - 10.18632/oncotarget.18596
M3 - Article
AN - SCOPUS:85032891835
SN - 1949-2553
VL - 8
SP - 93450
EP - 93463
JO - Oncotarget
JF - Oncotarget
IS - 55
ER -